Cargando…

Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada

Given the increasing role of patient groups in pharmaceutical policy-making in Canada, this observational study was undertaken to determine whether companies that are members of Innovative Medicines Canada (IMC) list, on their publicly available websites, the names of patient groups that they make d...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lexchin, Joel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kerman University of Medical Sciences 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808287/ https://www.ncbi.nlm.nih.gov/pubmed/35021614 http://dx.doi.org/10.34172/ijhpm.2021.172

Ejemplares similares

National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study
por: Lexchin, Joel, et al.
Publicado: (2022)

Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis
por: Lexchin, Joel
Publicado: (2018)

Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2020)

Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?
por: Lee, Shoo K., et al.
Publicado: (2023)

Canada and the pharmaceutical industry in the time of COVID-19
por: Lexchin, Joel
Publicado: (2023)

Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study
por: Norris, Susan L, et al.
Publicado: (2012)

Doctors’ opinions of information provided by Libyan pharmaceutical company representatives
por: Alssageer, Mustafa A., et al.
Publicado: (2012)

'Linkage' pharmaceutical evergreening in Canada and Australia
por: Faunce, Thomas A, et al.
Publicado: (2007)

Pharmaceutical security for Canada
por: Lee, Shoo K., et al.
Publicado: (2022)

Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective
por: Ahmadiani, Saeed, et al.
Publicado: (2016)

Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis
por: Eisenkraft Klein, Daniel, et al.
Publicado: (2023)

Complaints about Violations of Voluntary and Pharmaceutical Industry-Run Medicine Promotion Codes in Canada
por: Lexchin, Joel
Publicado: (2023)

Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016
por: Stoll, Marlene, et al.
Publicado: (2020)

Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
por: Mulinari, Shai, et al.
Publicado: (2018)

Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016
por: Shimada, Yuki, et al.
Publicado: (2019)

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
por: Fabbri, Alice, et al.
Publicado: (2018)

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
por: Lexchin, Joel, et al.
Publicado: (2014)

Patient Organizations’ Funding from Pharmaceutical Companies: Is Disclosure Clear, Complete and Accessible to the Public? An Italian Survey
por: Colombo, Cinzia, et al.
Publicado: (2012)

Medicine donations: a review of policies and practices
por: Permaul Flores, Hannah, et al.
Publicado: (2023)

A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada
por: Morgan, Steven G., et al.
Publicado: (2016)

Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review
por: Spurling, Geoffrey K., et al.
Publicado: (2010)

Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study
por: Lexchin, Joel
Publicado: (2022)

On the Adjustment of the Claims at Present Made by the Medical Profession on the Assurance Companies
por: Christison,
Publicado: (1850)

Tourism companies' risk exposures on text disclosure
por: Li, Jianping, et al.
Publicado: (2020)

Buyouts of Indian Pharmaceutical Companies by Multinational Pharmaceutical Companies: An Issue of Concern
por: Sreedhar, D, et al.
Publicado: (2011)

How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study
por: Lexchin, Joel
Publicado: (2020)

Models for financing the regulation of pharmaceutical promotion
por: Lexchin, Joel
Publicado: (2012)

The influence of pharmaceutical companies
por: Migone, Paolo
Publicado: (2017)

Good Pharmacovigilance Practice: Accountability of Ayurvedic Pharmaceutical Companies
por: Sharma, Rohit, et al.
Publicado: (2017)

Nicotine quantity and packaging disclosure in smoked and smokeless tobacco products in India
por: Sharma, Priyamvada, et al.
Publicado: (2015)

How and why patients made Long Covid
por: Callard, Felicity, et al.
Publicado: (2021)

The Pharmaceutical Industry and the Canadian Government: Folie à Deux
por: Lexchin, Joel
Publicado: (2017)

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Good pharmacovigilance practice: Need of the hour from pharmaceutical companies
por: Bhati, Neha, et al.
Publicado: (2015)

Pharmacovigilance in pharmaceutical companies: An overview
por: Mammì, Maria, et al.
Publicado: (2013)

Environmental and social disclosures dataset for Malaysian public listed companies
por: Rosman, Nor Syazwani, et al.
Publicado: (2023)

Marketing before patenting: implications for price controls in Canada
por: Lexchin, Joel
Publicado: (2010)

Health Canada's Proposal to Accelerate New Drug Reviews
por: Lexchin, Joel
Publicado: (2020)

Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
por: Stoll, Marlene, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p5137sgn5pv2ukrgudf6tjf4d7